Why Eli Lilly Is Cratering Today
Image source: Getty.
What happened
After releasing disappointing results from a late-stage clinical trial, shares of pharma giantEli Lilly (NYSE: LLY) fell by more than 12% as of 11:15 a.m. EST on Wednesday.
So what
The trial in question was called EXPEDITION3. This study was testing Lilly's experimental compoundsolanezumab as a hopeful treatment for mild dementia due to Alzheimer's disease. Solanezumab is a compound that is designed to reduce the amount of amyloid plaque that accumulates in the brain, which some scientists believe is linked to the development of Alzheimer's disease. Lilly had high hopes that this compound could turn into a megablockbuster drug that would offer hope to the millions of patients around the world that suffer from this awful disease.
Unfortunately, top-line results from the trial showed that patients who used solanezumab did not experience a statistically significant slowing of cognitive decline when compared to patients who only received a placebo. As a result, Lilly has decided not to move forward with regulatory submission.
Dr. John Lechleiter, Eli Lilly's CEO, expressed his disappointment with the data, stating, "The results of the solanezumab EXPEDITION3 trial were not what we had hoped for and we are disappointed for the millions of people waiting for a potential disease-modifying treatment for Alzheimer's disease."
Management stated that the study's outcome will result in a fourth-quarter charge of roughly $150 million, or approximately$0.09per share.The company plans on holding a conference call with investors on December 15 to share more details about the trial, and announce its 2017 financial guidance.
Now what
This news comes as a huge blow to patients and investors alike. Time has shown that developing new treatments for Alzheimer's disease has been incredibly difficult, and Lilly'ssolanezumab was one of the more promising near-term options.
Despite the setback, Eli Lilly's incoming CEODavid Ricks did his best to provide investors with a bullish case for owning the company's shares, stating: "Driven by new product launches, we continue to expect to grow average annual revenue by at least 5 percent between 2015 and 2020. Over that time frame, we also expect to increase our margins and provide annual dividend increases to our shareholders."
10 stocks we like better than Eli Lilly and Co. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Eli Lilly and Co. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 7, 2016
Brian Feroldi has no position in any stocks mentioned.Like this article? Follow him onTwitter where he goes by the handle@Longtermmindsetor connect with him on LinkedIn to see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.